| January 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 2, 2026 |
LLY |
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus |
Trial Milestone |
Phase 1 |
| January 2, 2026 |
INBS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 2, 2026 |
MGTX |
8-K filed: Material agreement |
Corporate |
— |
| January 2, 2026 |
VOR |
8-K filed: Leadership change |
Corporate |
— |
| January 2, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 2, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| January 2, 2026 |
GNLX |
8-K filed: Leadership change |
Corporate |
— |
| January 2, 2026 |
RNXT |
8-K filed: Listing / standard notice |
Corporate |
— |
| January 2, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| January 5, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| January 5, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
MRNA |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 5, 2026 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| January 5, 2026 |
TEVA |
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease |
Trial Milestone |
Phase 2 |
| January 5, 2026 |
IMUX |
8-K filed: Leadership change |
Corporate |
— |
| January 5, 2026 |
RNAC |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Trial Milestone |
Phase 2 |
| January 5, 2026 |
TNGX |
8-K filed: Leadership change |
Corporate |
— |
| January 5, 2026 |
GNLX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 5, 2026 |
DMAC |
8-K filed: Other event |
Filing |
— |
| January 5, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| January 5, 2026 |
AGEN |
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer |
Trial Milestone |
Phase 2 |
| January 5, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 6, 2026 |
PFE |
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults. |
Trial Milestone |
Phase 1 |
| January 6, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 6, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 6, 2026 |
ARWR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 6, 2026 |
ALKS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 6, 2026 |
PRAX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 6, 2026 |
DNLI |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 6, 2026 |
IMUX |
8-K filed: Listing / standard notice |
Corporate |
— |
| January 6, 2026 |
GERN |
8-K filed: Material agreement |
Corporate |
— |
| January 6, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| January 6, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| January 6, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| January 6, 2026 |
ANGO |
Quarterly results filed (8-K) |
Earnings |
— |
| January 6, 2026 |
MLYS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 6, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 6, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
PFE |
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) |
Trial Milestone |
Phase 3 |
| January 7, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| January 7, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| January 7, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| January 7, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 7, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 7, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 7, 2026 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 7, 2026 |
RAPP |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
RAPP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 7, 2026 |
CMPS |
8-K filed: Material agreement |
Corporate |
— |
| January 7, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 7, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| January 7, 2026 |
PHAT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 7, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| January 7, 2026 |
IMRX |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
KYNB |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
BFRI |
8-K filed: Listing / standard notice |
Corporate |
— |
| January 7, 2026 |
ORMP |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| January 7, 2026 |
OMER |
Quarterly results filed (8-K) |
Earnings |
— |
| January 7, 2026 |
TTRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| January 7, 2026 |
MBRX |
8-K filed: Other event |
Filing |
— |
| January 7, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 7, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 7, 2026 |
GNPX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 8, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
VNDA |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
INBS |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
PRAX |
8-K filed: Leadership change |
Corporate |
— |
| January 8, 2026 |
VSTM |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 8, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
MLTX |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
KRYS |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 8, 2026 |
IRD |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 8, 2026 |
AVIR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
IVVD |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
AMLX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 8, 2026 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
PHAT |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
PCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
GNLX |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
CLYM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 8, 2026 |
ARDX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
COYA |
8-K filed: Other event |
Filing |
— |
| January 8, 2026 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
TRDA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
SPRB |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
AGEN |
8-K filed: Material agreement |
Corporate |
— |
| January 8, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
ACRV |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 8, 2026 |
ACRV |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
CRIS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 8, 2026 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 8, 2026 |
CGEM |
Quarterly results filed (8-K) |
Earnings |
— |
| January 8, 2026 |
SXTP |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 8, 2026 |
ILMN |
Dr. Eric Green Appointed Chief Medical Officer |
Corporate |
— |
| January 8, 2026 |
ILMN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| January 9, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
ARWR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 9, 2026 |
INSM |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 9, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| January 9, 2026 |
LQDA |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
URGN |
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) |
Trial Milestone |
Phase 1 |
| January 9, 2026 |
RYTM |
Quarterly results filed (8-K) |
Earnings |
— |
| January 9, 2026 |
IMCR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 9, 2026 |
VTGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
CGON |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 9, 2026 |
RNAC |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
TENX |
8-K filed: Leadership change |
Corporate |
— |
| January 9, 2026 |
SVRA |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
QURE |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
ALMS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 9, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
LONA |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| January 9, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 9, 2026 |
MPLT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 9, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
BCRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 9, 2026 |
BCLI |
8-K filed: Material agreement |
Corporate |
— |
| January 9, 2026 |
TPST |
8-K filed: Listing / standard notice |
Corporate |
— |
| January 9, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 9, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
LLY |
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 3 |
| January 12, 2026 |
BMY |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
ARGX |
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis |
Trial Milestone |
Phase 3 |
| January 12, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
IONS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
AGIO |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
EXEL |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
RARE |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
JAZZ |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
AXSM |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
ALNY |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
MRNA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
MIRM |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
ARWR |
8-K filed: Material agreement |
Corporate |
— |
| January 12, 2026 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
NUVB |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
XENE |
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
Trial Milestone |
Phase 3 |
| January 12, 2026 |
SMMT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
IDYA |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
TEVA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
REPL |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
KARD |
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) |
Trial Milestone |
Phase 2 |
| January 12, 2026 |
VIR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
SRPT |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
CABA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 12, 2026 |
ANNX |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
TVTX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
BCYC |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
DYN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
KRYS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
IRD |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
OLMA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
SNDX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
VOR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
PTGX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
GERN |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
NVCR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
GRCE |
8-K filed: Leadership change |
Corporate |
— |
| January 12, 2026 |
CRBP |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
NRIX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
MBX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
BEAM |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
STOK |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
BCAX |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
KURA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
LRMR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
KNSA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
KYTX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
PROK |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
LXEO |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 12, 2026 |
SYRE |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
RXRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
CRSP |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 12, 2026 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
WVE |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
XFOR |
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function |
Trial Milestone |
Phase 1 |
| January 12, 2026 |
ERAS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 12, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| January 12, 2026 |
TCRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
ACTU |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 12, 2026 |
AKBA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
CERS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 12, 2026 |
BIOA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 12, 2026 |
RIGL |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| January 13, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 13, 2026 |
TGTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 13, 2026 |
ACAD |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
TVTX |
8-K filed: Other event |
Filing |
— |
| January 13, 2026 |
GKOS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
CGON |
8-K filed: Other event |
Filing |
— |
| January 13, 2026 |
VCEL |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 13, 2026 |
QURE |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 13, 2026 |
MAIA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 13, 2026 |
TRAW |
8-K filed: Other event |
Filing |
— |
| January 13, 2026 |
BFRI |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
KYMR |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| January 13, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 13, 2026 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| January 13, 2026 |
ILMN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 14, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| January 14, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 14, 2026 |
IBRX |
8-K filed: Other event |
Filing |
— |
| January 14, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| January 14, 2026 |
ANNX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 14, 2026 |
PVLA |
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations |
Trial Milestone |
Phase 3 |
| January 14, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 14, 2026 |
KNSA |
8-K filed: Leadership change |
Corporate |
— |
| January 14, 2026 |
ANGO |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 14, 2026 |
ORMP |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 14, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| January 14, 2026 |
AGEN |
8-K filed: Leadership change |
Corporate |
— |
| January 15, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| January 15, 2026 |
ABBV |
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| January 15, 2026 |
SVA |
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) |
Trial Milestone |
Phase 2 |
| January 15, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| January 15, 2026 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 15, 2026 |
FDMT |
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease |
Trial Milestone |
Phase 1/Phase 2 |
| January 15, 2026 |
OCGN |
8-K filed: Other event |
Filing |
— |
| January 15, 2026 |
BSX |
8-K filed: Material agreement |
Corporate |
— |
| January 15, 2026 |
BSX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 15, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| January 15, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| January 15, 2026 |
OMER |
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN |
Trial Milestone |
Phase 2 |
| January 15, 2026 |
BCTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 16, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| January 16, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
LPCN |
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD |
Trial Milestone |
Phase 3 |
| January 16, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| January 16, 2026 |
AGEN |
8-K filed: Acquisition completed, Reg FD disclosure |
Corporate |
— |
| January 16, 2026 |
CNSY |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 19, 2026 |
LLY |
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity |
Trial Milestone |
Phase 1 |
| January 19, 2026 |
MRNA |
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine |
Trial Milestone |
Phase 2 |
| January 20, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 20, 2026 |
LLY |
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities |
Trial Milestone |
Phase 3 |
| January 20, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 20, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| January 20, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 20, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| January 20, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 20, 2026 |
CRVS |
8-K filed: Other event |
Filing |
— |
| January 20, 2026 |
CRVS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 20, 2026 |
MAIA |
8-K filed: Other event |
Filing |
— |
| January 20, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 20, 2026 |
COYA |
8-K filed: Other event |
Filing |
— |
| January 20, 2026 |
ERAS |
Quarterly results filed (8-K) |
Earnings |
— |
| January 20, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| January 20, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 20, 2026 |
BIOA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 20, 2026 |
ILMN |
TruSight Oncology Comprehensive — CMS Reimbursement |
Regulatory |
— |
| January 21, 2026 |
JNJ |
Quarterly results filed (8-K) |
Earnings |
— |
| January 21, 2026 |
OCGN |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 21, 2026 |
ALXO |
8-K filed: Leadership change |
Corporate |
— |
| January 21, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 21, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| January 22, 2026 |
LLY |
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) |
Trial Milestone |
Phase 3 |
| January 22, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| January 22, 2026 |
CORT |
8-K filed: Other event |
Filing |
— |
| January 22, 2026 |
UTHR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| January 22, 2026 |
MBX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| January 22, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| January 22, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| January 22, 2026 |
BIOA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| January 23, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| January 23, 2026 |
OCUL |
8-K filed: Leadership change |
Corporate |
— |
| January 23, 2026 |
OCGN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 23, 2026 |
CRVS |
8-K filed: Other event |
Filing |
— |
| January 23, 2026 |
BCRX |
8-K/A filed: Leadership change |
Corporate |
— |
| January 23, 2026 |
BCRX |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| January 23, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 23, 2026 |
RVPH |
8-K filed: Listing / standard notice, Other event |
Corporate |
— |
| January 23, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| January 23, 2026 |
CERS |
8-K filed: Leadership change |
Corporate |
— |
| January 23, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 23, 2026 |
SXTP |
8-K filed: Listing / standard notice, Reg FD disclosure |
Corporate |
— |
| January 26, 2026 |
LLY |
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight |
Trial Milestone |
Phase 1 |
| January 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 26, 2026 |
ABBV |
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) |
Trial Milestone |
Phase 2 |
| January 26, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 26, 2026 |
IBRX |
8-K filed: Material agreement |
Corporate |
— |
| January 26, 2026 |
MIRM |
8-K filed: Acquisition completed, Reg FD disclosure, Other event |
Corporate |
— |
| January 26, 2026 |
KLRA |
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight |
Trial Milestone |
Phase 1 |
| January 26, 2026 |
STOK |
8-K filed: Material agreement |
Corporate |
— |
| January 26, 2026 |
OTLC |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| January 26, 2026 |
TRAW |
8-K filed: Other event |
Filing |
— |
| January 26, 2026 |
BTMD |
8-K filed: Other event |
Filing |
— |
| January 26, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| January 27, 2026 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| January 27, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| January 27, 2026 |
NKTR |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 27, 2026 |
SVRA |
8-K filed: Material agreement |
Corporate |
— |
| January 27, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| January 27, 2026 |
LXEO |
8-K filed: Leadership change |
Corporate |
— |
| January 28, 2026 |
PFE |
A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults |
Trial Milestone |
Phase 1 |
| January 28, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 28, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 28, 2026 |
TEVA |
Quarterly results filed (8-K) |
Earnings |
— |
| January 28, 2026 |
RGNX |
8-K filed: Other event |
Filing |
— |
| January 28, 2026 |
ANVS |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 28, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 28, 2026 |
NRIX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 28, 2026 |
CRVS |
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD |
Trial Milestone |
Phase 1 |
| January 28, 2026 |
PCRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| January 28, 2026 |
ALT |
8-K filed: Material agreement |
Corporate |
— |
| January 28, 2026 |
HALO |
Quarterly results filed (8-K) |
Earnings |
— |
| January 28, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| January 28, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 28, 2026 |
AMRX |
8-K filed: Other event |
Filing |
— |
| January 28, 2026 |
TPST |
8-K filed: Leadership change |
Corporate |
— |
| January 29, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 29, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| January 29, 2026 |
REGN |
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults |
Trial Milestone |
Phase 1 |
| January 29, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| January 29, 2026 |
JAZZ |
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 |
Trial Milestone |
Phase 1 |
| January 29, 2026 |
BMRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| January 29, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| January 29, 2026 |
DFTX |
8-K filed: Leadership change |
Corporate |
— |
| January 29, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| January 29, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 29, 2026 |
BEAM |
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects |
Trial Milestone |
Phase 1 |
| January 29, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| January 29, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| January 29, 2026 |
LXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| January 29, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| January 30, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| January 30, 2026 |
JNJ |
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer |
Trial Milestone |
Phase 1 |
| January 30, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| January 30, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| January 30, 2026 |
MDGL |
8-K filed: Material agreement |
Corporate |
— |
| January 30, 2026 |
IMCR |
8-K filed: Leadership change |
Corporate |
— |
| January 30, 2026 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| January 30, 2026 |
ALXO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| January 30, 2026 |
ALXO |
8-K filed: Other event |
Filing |
— |
| January 30, 2026 |
OLMA |
8-K filed: Leadership change |
Corporate |
— |
| January 30, 2026 |
COYA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| January 30, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 30, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| January 30, 2026 |
HURA |
8-K filed: Listing / standard notice |
Corporate |
— |
| January 30, 2026 |
AKBA |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| January 30, 2026 |
ILMN |
SomaLogic & Sengenics Acquisition Closed |
Corporate |
— |
| January 30, 2026 |
ILMN |
8-K filed: Acquisition completed, Other event |
Corporate |
— |
| January 31, 2026 |
PVCT |
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency |
Trial Milestone |
Phase 4 |